Dengue vaccine development: challenges and prospects

Curr Opin Infect Dis. 2022 Oct 1;35(5):390-396. doi: 10.1097/QCO.0000000000000871.


Purpose of review: Dengue vaccine development is a high public health priority. To date, no dengue vaccine is in widespread use. Here we review the challenges in dengue development and the latest results for the second-generation dengue vaccines.

Recent findings: The biggest hurdle is the immunological interaction between the four antigenically distinct dengue serotypes. The advantages of second-generation dengue vaccines are the inclusion of nonstructural proteins of the dengue backbone and a more convenient dosing with reduced numbers of doses needed.

Summary: Although dengue-primed individuals can already benefit from vaccination with the first licensed dengue vaccine CYD-TDV, the public health need for the dengue-naive population has not yet been met. The urgent need remains to identify correlates of both protection and enhancement; until such correlates have been identified, all second-generation dengue vaccines still need to go through full phase 3 trials. The 5-year efficacy and safety data for both second-generation dengue vaccines are imminent.

Publication types

  • Review

MeSH terms

  • Dengue Vaccines*
  • Humans
  • Public Health
  • Vaccination / methods


  • Dengue Vaccines